Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Brigatinib布加替尼 ,Brigatinib,布吉他滨,布格替尼

Bukitabine was approved by the FDA on April 28, 2017 for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) with disease progression or intolerance after crizotinib treatment.
Bujibine is a tyrosine kinase inhibitor that can inhibit abnormal activation caused by ALK fusion and inhibit tumor cell proliferation.